期刊
CLINICAL NEUROPHARMACOLOGY
卷 33, 期 5, 页码 243-247出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNF.0b013e3181f5329e
关键词
botulinum toxin A; spasticity; botulism; dose response relationship; idiosyncratic adverse reaction
资金
- National Institutes of Health
- Robert Wood Johnson Foundation
- Michael J. Fox Foundation
- National Institute for Environmental Health Sciences [K24ES017765]
- National Institute of Neurological Disorders and Stroke [5T32NS007205-27, 1K08NS064365-01A1]
- National Center for Research Resources [NCRR0]
- National Institutes of Health Roadmap for Medical Research [UL1 RR024992, KL2RR024994, UL1RR024992]
The use of intramuscular injections of Botulinum neurotoxin A (BoNT-A) is common in the treatment of hypertonicity and movement disorders. Although most side effects are mild, systemic effects, manifested by generalized weakness distant from the site of injection, have been reported. Previously reported occurrences are discussed, and 3 new cases of patients, who developed systemic weakness after administration of BoNT-A (Botox), despite having tolerated similar injections on several previous occasions, are presented. A review of the literature and reported cases indicate that risk of developing systemic effects does not seem to be related to dose based on body weight. It may be more likely that risk for systemic effects is related to total injection dose and injection frequency. The results of our 3 patients would indicate that injections of greater than 600 units of Botox with follow-up injections occurring every 3 months may lead to an increased risk. We would recommend careful consideration of reinjection frequency if injections of greater than 600 units of Botox are given. Reduction in systemic side effects may occur if reinjection frequency occurs in intervals of 4 months or greater in these individuals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据